|
1. SIR-Spheres
® was approved by the Food and
Drug Administration as...:
a
soluble radiopharmaceutical
a
colloidal radiopharmaceutical
an
implantable radiotherapeutic device
an
unsealed source in the body
|
|
2. The
average diameter of Y-90 Microspheres is approximately...:
0.3 mm
3.0 mm
30 mm
300 mm
|
|
3. Y-90
decays by...?:
alpha
emission
pure beta emission
beta/gamma
emission
electron
capture
|
|
4.
The
half-life of Y-90 is...?:
2.5
min
2.5
hours
2.5 days
2.5 weeks
|
|
5.
The
goal of treating liver metastases with Y-90 Microspheres is to...?
deliver
a very large radiation dose to the entire liver
deliver
a tumoricidal dose to the metastases while minimizing the dose to normal liver
tissue
shrink
the tumor with an external radiation beam so it may then be removed surgically
destroy
tumor cells so a liver transplant can then be performed
|
|
6. The
number of Microspheres delivered during a typical injection number
approximately...?:
500,000
5,000,000
50,000,000
500,000,000
|
|
7. Successful administration of Y-90
Microspheres is typically performed by...:
a
radiologist
a nuclear physician
a radiochemist
and a nurse
a
multi-disciplinary team
|
|
8. Therapy
of liver metastases with Y-90 Microspheres is successful because which one of
the following statements is TRUE?:
80%
of the blood supply to liver tumors derives from the hepatic artery and 80% of
the blood supply to normal liver tissue derives from the portal vein
80%
of the blood supply to liver tumors derives from the hepatic artery and 20% of
the blood supply to normal liver tissue derives from the portal vein
20%
of the blood supply to liver tumors derives from the hepatic artery and 80% of
the blood supply to normal liver tissue derives from the portal vein
20%
of the blood supply to liver tumors derives from the hepatic artery and 20% of
the blood supply to normal liver tissue derives from the portal vein
|
|
9. Which
ONE of the following patients is eligible to undergo Selective Internal
Radiation Therapy?:
Patient
has elevated bilirubin level; shunting to lungs is 10%
Has
normal bilirubin level, lung shunting is 27%
Has
normal bilirubin level, lung shunting is
10%
None
of the above
|
|
10. The
maximum % of lung shunting that is acceptable for inclusion in the study is...?
5%
10%
15%
20%
|
11.
If
% of
lung shunting is 15 %?
No
dose adjustment is required
Patient
study must not be performed
Dose
adjustment is required
It
is impossible to measure shunting to the lung
|
12.
. Which of the following is/are
an eligibility requirement for participation in the study?
Extensive angiographic workup Patient ineligible for liver
transplant
Good renal and hepatic function
All
of the above
|
13.
The percent shunting to the lungs is determined by...?
an FDG PET scan a lung biopsy
a Tc-99m MAA study
a Tc-99m Sulfur colloid study
|
14.
The maximum tolerable
radiation dose to the lungs before pulmonary fibrosis occurs is
...?
0.3 Gy 3 Gy
30 Gy
300 Gy
|
15.
Which one of the following statements is FALSE?
This study must be
precertified by the insurance company before the dose is ordered
Either one lobe or the whole
liver may be treated
The
BSA Method of dose determination is based on the patient’s Body
Surface Area as well as the % tumor involvement
The
typical dose administered is 0.1 GBq
|
16.
Which of the following are
expected side effects of the SIRT procedure?
Nausea
Lethargy
Gastritis
All
of the above
None
of the above
|
17.
Which one of the following
emissions from Y-90 in the patient’s liver can be used for a post-dose
image to insure correct localization...?
High-energy b- particles Medium energy g-rays
Bremsstrahlung X-rays
Auger electrons
|
18.
Regarding post-treatment
planning, which ONE of the following is NOT recommended...?
Single use room Minimize number and length of
visits by friends and family
Nursing
services delivered on RIGHT side of patient
Only non-pregnant
staff/visitors present
|
19.
After discharge, which one of
the following is NOT recommended??
antibiotic for 5 days to
prevent infection pain medication and anti-nausea
medication as needed
patient should be well-hydrated
patient
must remain in bed for 7 days before resuming normal activities
|
20.
Which
ONE of the following procedures is valuable for long-term follow-up of
the patient
...?
Review of patient’s
medication and pain diaries Tc-MAA lung scan
Tc-99m SC liver scan
F-18
FDG PET scan
|
